Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0001746372-26-000002
Filing Date
2026-02-23
Accepted
2026-02-23 16:05:56
Documents
1
Period of Report
2026-02-20

Document Format Files

Seq Description Document Type Size
1 FORM 4 wk-form4_1771880754.html 4  
1 FORM 4 wk-form4_1771880754.xml 4 3248
  Complete submission text file 0001746372-26-000002.txt   4715
Mailing Address #140, 14315 - 118 AVENUE EDMONTON A0 T5L 4S6
Business Address #140, 14315 - 118 AVENUE EDMONTON A0 T5L 4S6 250-744-2487
Aurinia Pharmaceuticals Inc. (Issuer) CIK: 0001600620 (see all company filings)

EIN.: 981231763 | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address C/O AURINIA PHARMACEUTICALS INC. #140, 14315-118 AVENUE EDMONTON Alberta, Canada T5L 4S6
Business Address
Miller Joseph M (Reporting) CIK: 0001746372 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-36421 | Film No.: 26665111